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Ribonucleases (RNases) are a large number of enzymes gathered into different bacterial
or eukaryotic superfamilies. Bovine pancreatic RNase A, bovine seminal BS-RNase,
human pancreatic RNase 1, angiogenin (RNase 5), and amphibian onconase belong to
the pancreatic type superfamily, while binase and barnase are in the bacterial RNase
N1/T1 family. In physiological conditions, most RNases secreted in the extracellular
space counteract the undesired effects of extracellular RNAs and become protective
against infections. Instead, if they enter the cell, RNases can digest intracellular RNAs,
becoming cytotoxic and having advantageous effects against malignant cells. Their
biological activities have been investigated either in vitro, toward a number of different
cancer cell lines, or in some cases in vivo to test their potential therapeutic use. However,
immunogenicity or other undesired effects have sometimes been associated with their
action. Nevertheless, the use of RNases in therapy remains an appealing strategy
against some still incurable tumors, such as mesothelioma, melanoma, or pancreatic
cancer. The RNase inhibitor (RI) present inside almost all cells is the most efficacious
sentry to counteract the ribonucleolytic action against intracellular RNAs because it
forms a tight, irreversible and enzymatically inactive complex with many monomeric
RNases. Therefore, dimerization or multimerization could represent a useful strategy for
RNases to exert a remarkable cytotoxic activity by evading the interaction with RI by
steric hindrance. Indeed, the majority of the mentioned RNases can hetero-dimerize
with antibody derivatives, or even homo-dimerize or multimerize, spontaneously or
artificially. This can occur through weak interactions or upon introducing covalent bonds.
Immuno-RNases, in particular, are fusion proteins representing promising drugs by
combining high target specificity with easy delivery in tumors. The results concerning
the biological features of many RNases reported in the literature are described and
discussed in this review. Furthermore, the activities displayed by some RNases forming
oligomeric complexes, the mechanisms driving toward these supramolecular structures,
and the biological rebounds connected are analyzed. These aspects are offered with
the perspective to suggest possible efficacious therapeutic applications for RNases
oligomeric derivatives that could contemporarily lack, or strongly reduce, immunogenicity
and other undesired side-effects.
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INTRODUCTION
RNases
Ribonucleases (RNases) form a very large group of bacterial
or eukaryotic enzymes that have been deeply studied in the
last 50–60 years (1). RNases catalyze the hydrolysis of a
variety of different RNA substrates (2), so that a logical and
suitable classification in families may not be easy or immediate.
Furthermore, a cell contains a large number of distinct RNases,
approaching as many as twenty members, often characterized
by different or sometimes overlapping substrate specificities (3).
However, notwithstanding this complexity, a useful classification
may descend from differentiating intracellular RNases from the
ones secreted in extracellular fluids that are also called secretory
RNases (1, 4, 5), on which we will focus our attention.
Pancreatic-Type RNases
The group of secretory RNases has included, since the 60s,
an increasing number of members that have been discovered,
characterized and classified as the “pancreatic-type” RNases (5,
6). This definition originates from the bovine pancreatic RNase
A, a 13.7 kDa and 124 AA residues enzyme that has been the
most studied RNase in the past (7–10). The already 20 years
old review of Raines still remains an exhaustive milestone that
describes many aspects of RNase A, especially its catalytic activity
(11). More recently, RNases of the pancreatic-type superfamily
proto-type do not refer sometimes to the bovine variant but to
human pancreatic RNase (12), called HP-RNase or RNase 1 (6).
This variant is not expressed only in the pancreas, but in almost
all tissues (13), and displays a highly similar identity sequence
as RNase A, although the former is more basic than the latter
(14). Both RNase A and RNase 1 can be variably glycosylated at
the expense of some Asn residues, especially Asn34, with RNase
1 being more prone to suffer this modification than the former
(15, 16). Besides these two members, other important RNases
have been included in the mentioned superfamily although
they are not secreted by the pancreas: deserving notice are the
cytotoxic bovine seminal RNase (BS-RNase) (17), the unique
natively dimeric member of the superfamily (18, 19), and also
RNase 5 or angiogenin (ANG) (20). ANG is 123 AA residues
long and is so called because of its active role in the new vessels
formation, but it exerts ribonucleolytic activity against tRNAs as
well (21–23). Again, other RNases belonging to non-mammalian
species, such as birds or amphibians, are also known (24, 25).
Among these RNases, the most studied are the 114 AA residues
amphinase and, above all, the smallest variant called ranpirnase
or P-30 protein, which is formed only by 104AA residues (26, 27).
This latter variant is commonly called onconase (ONC) because
of its remarkable antitumor activity exerted against many cancer
types (27, 28). Although not being mammalian, both amphinase
and ONC have been included in the pancreatic-type superfamily
because of their structural homology with pancreatic RNases,
being characterized only by about 30% sequence identity (28).
Hence, the main general requisites necessary to belong to the
pancreatic-type superfamily are (i) the conservation of a catalytic
triad formed by one Lys and two His residues, as H12/K41/H119
is for RNase A, (ii) an elevated homology folding resembling the
V-like, or kidney-like shape of RNase A and (iii) the distribution
of the basic charged residues that should be almost totally located
in the proximity of the active site region (5) to allow an efficacious
accommodation of the negatively charged RNA polymer in the
RNase active site cavity (29). Therefore, many of the mentioned
basic residues are considered “subsites” crucial for an optimal
catalysis (11, 30) or they are sometimes considered even as
secondary active sites, as was recently reported for human RNase
6 (31). This aspect acquires increasing importance if we recall that
RNases can often interact with a polymeric substrate and not only
with short oligonucleotides (29).We also point out Arnold’s quite
interesting review in which the principal features of mammalian
and amphibian RNases have been exhaustively compared (25).
Mammalian and Amphibian Secretory
RNases and Their Biological Activities
Up to eight secretory RNase variants, numbered from 1 to 8,
have been characterized today in humans. The alreadymentioned
pancreatic RNase 1 is expressed in all tissues, but it is particularly
abundant in endothelial cells (32). Its biological activity features
are devoted to controlling the extracellular RNA (exRNA)
content in the biological fluids, as will be reported below.
RNases 2 and 3 are instead highly basic eosinophil secretory
variants that reciprocally share 67% identity but only 32 and
26% with RNase 1, respectively. They are both out of the
“pancreatic-type” superfamily because their basic residues are
randomly located (5). However, the 134 AA residues long RNase
2 displays an activity against yeast RNA comparable with the one
of the pancreatic enzyme (33). RNase 2 is the eosinophil-derived
neurotoxin (EDN) that is additionally present in many organs
and fluids (34, 35). EDN/RNase 2 elicits Purkinje cells death when
released into the cerebellum, but it exerts crucial physiological
actions taking part in the innate host defense (36). It is
released from eosinophilic granules in response to inflammatory
mediators, supporting an immune-modulatory role (37). In
particular, cytokines, such as CCL11 and CCL24 can induce
RNase 2 and also RNase 3 secretion via the PI3K/MAPK pathway
(38, 39). In addition, RNase 2 displays chemoattractant effects
by eliciting both dendritic cells’ maturation and activation and
also exerts activity against both Respiratory Syncytial andHuman
Immunodeficiency Viruses (36, 39). Indeed, virus infection can
trigger eosinophilic RNases release through the toll-like receptors
signaling pathways (39). Differently from EDN, the 133 AA
residues RNase 3 is eosinophil-specific and is also named the
eosinophil cationic protein (ECP) (40, 41). ECP is peculiar in
the RNase world: in fact, although it is less neurotoxic than
EDN, it exerts remarkable bactericidal effects, promoting the
agglutination of bacteria cells and cytotoxicity (42) also when
its catalytic activity is nil (43). Several inflammatory stimuli
trigger ECP release, so that its serum concentration is used as
a biomarker of various Th2-phenotype-associated inflammatory
diseases, including asthma, allergic rhinitis, dermatitis and bowel
disease (44, 45). Furthermore, and differently from the other
wt-RNases, ECP can form amyloid-like fibrils at acidic pH (46).
RNase 4 (119 AA residues) is today the least studied human
RNase variant, although its ubiquitous expression suggests for
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it an important physiological role (36). It is highly selective for
uridine RNA sites of cleavage (47, 48), and, similarly to RNase
5, RNase 4 displays angiogenic activity (47, 49). Consequently,
it is protective against neuron degeneration by promoting
angiogenesis, neurogenesis and neuronal survival under stress
(50). Importantly, polymorphisms, and recently, pathogenic
mutations have associated RNase 4 with Amyotrophic Lateral
Sclerosis (ALS) development (51, 52).
The already mentioned 123 AA RNase 5, or ANG, is
considered the oldest pancreatic type RNase member (53). It
displays three instead of four paired cysteines with respect
to the other RNases (24, 53), and its ribonucleolytic activity,
although being very low, is mandatory for its angiogenetic
action (36, 54). Its localization is also very important for its
somehow contradictory biological functions exerted in different
cell compartments and conditions. In fact, in the extracellular
space, ANG can trigger growth signaling pathways, such as
ERK1/2 and AKT activation, upon its binding to a receptor;
however, it is not well-characterized yet (54, 55). Inside the cells,
instead, its high affinity binding with the cellular ribonuclease
inhibitor (RI) switches off its catalytic and biological activities
(55). However, not all ANG molecules are sequestered by RI:
indeed, the phosphorylated ones can escape RI and enter the
nucleus, accumulating in the nucleolus where ANG stimulates
ribosomal transcription and exerts its angiogenetic activity (56).
In cancer cells, the increase of rRNA production and angiogenesis
definitely enhances cell growth and tumor progression (56).
Therefore, ANG inhibition can on one hand counteract tumor
growth, but, at the same time, could also promote neuronal
damage. In fact, as for RNase 4, many loss of function ANG
mutants are associated with ALS and/or Parkinson’s disease (57–
59). In the contrast of its nuclear activity, ANG can address
itself in the stress granules where it splits tRNA into fragments
(tRFs) (60). In this case, ANG can perform different functions
through an RNA interference-like mechanism (61). Indeed, ANG
is known to trigger the formation of cytotoxic tRFs species upon
knockdown of RI (62). Consequently, an induced cell death
effect can prevail over ANG angiogenetic action. In conclusion,
under different conditions ANG can induce either cell death or
survival (61, 63).
The 127 AA residues long RNase 6 (64), characterized by
two catalytic centers (31), is ubiquitously distributed, including
neutrophils and monocytes. RNase 6 is thought to exert an active
role in inflammation because its level increases in the urinary
tract after infection (65). The antimicrobial properties of this
variant are carried out by inducing bacteria agglutination (66).
Furthermore, RNase 6, as well as RNase 3, is highly effective
againstMycobacterium aurum by inducing an autophagy process
in the infected macrophages (67).
Finally, RNase 7 and 8 are formed by 128 and 127 AA residues,
respectively, displaying high structural similarity, although the
former is expressed in the skin but also in other epithelial
tissues and organs and can be induced by growth factors,
cytokines and bacterial products (68). Conversely, RNase 8 is
principally expressed in the placenta but also in the spleen,
lung and testis (69), implying the presence of a defense system
against pathogens that cross the placenta to target the fetus (70).
Importantly, we underline that the most important features of
the eight human variants are well-described in the two reviews
provided by Sorrentino and, more recently, by the group lead by
Boix (39, 71).
From what has been reported, the peculiar and remarkable
biological activities exerted by many RNases would not seem
at first to be directly related to their ability to hydrolyze RNA.
Instead, for the already mentioned BS-RNase, ANG, ONC,
and amphinase, at least a minimal ribonucleolytic activity is
mandatory to express their biological actions (72), among which
the cytotoxicity against malignant cells emerges (49, 73, 74),
while since the 70s, BS-RNase has been discovered to be also
immunosuppressive, embryotoxic, and aspermatogenic (73, 75–
77). Interestingly, the history of the findings related to the
antitumor action of many RNases has been well-described by
Matousek in 2001 (78).
Bacterial RNases
Considering their structural and functional properties, we report
about four bacterial RNases belonging to the RNase N1/T1
microbial superfamily (79). They are as follows: barnase from
Bacillus amyloliquefaciens (80–82), binase from B. pimulus (82,
83), balifase from B. licheniformis (84), and balnase from B.
altitudinis (85). Barnase is found to be bound with its inhibitor
Barstar (80, 81, 86), but when it dimerizes and contemporarily
forms a dibarnase immuno-derivative it exerts a remarkable
antitumor activity against many cancer cell types (87–89). Binase
is natively dimeric (83, 90), and possesses remarkable cytotoxic
and antiviral activities against transformed myeloid cells and
fibroblasts, also against SiHa cervix human papilloma virus-
infected carcinoma cells, without inducing immune response
(83, 91–93). In addition, a molecular mechanism that is
carried out without catalytic degradation of RNAs has been
suggested by Ilinskaya et al. to explain some binase anti-
tumor effects. Indeed, binase is reported to interact with
KRAS, stabilizing the inactive GDP-bound conformation of
RAS, thereby inhibiting MAPK/ERK signaling (94). Balifase
is then the most stable variant of this group and is not
natively dimeric, but it combines parts of binase and barnase
features (84). Balnase is almost identical to binase except for its
A106T mutated residue (85). However, its biological activities,
as well as the ones of balifase, have not been investigated
enough yet.
RNases belonging to the T2 family, whose human variant
is named RNASET2, also deserve to be mentioned for
their remarkable biological activities: they are found in
bacteria, plants and viruses but also in animals, and they
exert their enzymatic activity at pH values around 4–5—
indeed lower than neutral pH, around which the majority
of RNases are active (95). RNASET2 is secreted by damaged
tissues, exhibits chemotactic activity and initiates immune
response(s): in fact, recombinant RNASET2 injection induces
fibroplasias, connective tissue remodeling and the recruitment
of infiltrating cells expressing macrophage markers (96).
Furthermore, humans lacking or carrying RNASET2 mutations
suffer neurological disorders or even misfunction in the immune
system (97).
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Secretory RNases as Natural Scavengers
of Extracellular RNA (exRNA)
The ca. 20 active RNases present in almost all mammalian
cell types process RNA into mature forms to regulate RNA
turnover and metabolism and properly tune the associated
cellular processes (98, 99). Additionally, RNases can also work
as alarming sentinels to block several cellular dysfunctions:
indeed, they can act as immune regulators or agents inducing
tissue repair and remodeling, epithelial barrier protection,
body fluid sterility and exRNA clearance (39). Regarding this
latter aspect, exRNA promotes the activation of proteases
that trigger the blood coagulation factors XI and XII, while a
RNase A pretreatment can delay occlusive thrombi formation
(100). Moreover, exRNA mediates the endothelial brain
permeability and RNase A treatment reduces vessel occlusion,
preventing brain edema (101). Furthermore, the in vivo
administration of RNase 1 reduced pathological parameters
that are characteristic for ischemia/reperfusion injury, thus
improving functional myocardial recovery (102). Finally,
considering that exRNA is able to increase inflammation by
stimulating leukocyte adhesion, transmigration and mobilization
of pro-inflammatory cytokines (103), secretory RNases can
become crucial modulators of physiological cell functions by
acting as natural exRNA scavengers.
Moreover, it has been recently discovered that exRNAs,
especially non-coding ones secreted from tumor cells, can act
as signals that modify the cell microenvironment and favor
tumor progression and metastasis formation (104). The largest
part of exRNA released in body fluids is encapsulated inside
extracellular vesicles and exosomes or is associated with high
density lipoproteins (105, 106). Thus, even if in these vesicles
exRNA is more protected, most secretory RNases are able to
cross the membrane, as it is reported hereinafter, thus exerting
an anti-tumor activity to counteract metastatic processes also at
the extracellular level (107).
In general, human secretory RNases also display anti-
inflammatory, antibacterial and antiviral actions, or induce
immune response when a large amount of ds-RNA is generated
by pathogens (53, 108). Additionally, RNase 1 is active against
DNA:RNA hybrids, and ds-RNA rather than ss-RNA (12, 109,
110), and, to this end, the conservation of its Gly38 residue is
crucial to maintaining the full catalytic activity against duplex
RNAs (111). Overall, many steps forward have been performed
in the comprehension of the antimicrobial effects ascribable
to many RNases, and promising results suggest their potential
use despite the classic antibiotics that lose efficacy upon the
development of resistance (31, 44, 112).
In summary, almost all the biological activities displayed
by the mentioned RNases are strictly dependent on their
ribonucleolytic activity vs. ss- and ds-RNA, necessary to
regulating the extracellular RNA level (36, 39, 100, 113).
The secreted RNases endowed with relevant biological
activities do not display their action only extracellularly, but
they are often able to enter the cell to exert their peculiar
activities against intracellular RNAs. However, at this step, many
difficulties indeed emerge, such as the necessity to have a
favorable interaction with cell membranes, a subsequent release
in the cytosol and the possibility to evade RI (114). These
issues are more extensively described in the next chapters,
together with the ability of RNases to form supramolecular
structures. The formation of oligomeric moieties can become in
fact advantageous for many RNases in terms of acquiring new
activities or potentiating pre-existing ones, as well as minimizing
undesired interactions, or also reducing adverse side effects
in vivo (115–117).
CRUCIAL STEPS FOR CYTOTOXIC
EXTRACELLULAR RNASES TO EXERT
THEIR ACTIVITY
Interaction With (Malignant) Cell
Membrane and Cell Entering Upon
Endocytosis
The main obstacle for extracellular RNases to exert their
antitumor action is represented by the possible difficulty to be
cellularly internalized. This occurs through endocytosis (118)
and only if a fruitful interaction with the cell membrane occurs.
However, the possibility for ONC to be internalized with the
mediation of a receptor has been proposed and debated as well
(119, 120). Sundlass et al. compared the ability of RNase 1,
RNase A and ONC to interact with lipid bilayers, revealing that
either electrostatic forces or specific interactions determining the
time spent by an RNase near the cell surface are critical for its
internalization (121). In addition, Notomista et al. demonstrated
that cytotoxic native or engineered dimeric RNases strongly affect
membrane aggregation, fluidity and fusion (122). Considering
that the most desired biological activity of RNases is to be
selectively cytotoxic against malignant cells and that these cells
possess a more negatively charged membrane than normal ones,
the basicity of each RNase is likely the most important feature
necessary to win this challenge. However, the basic net charge
per se is not enough for a RNase to be internalized in the cell.
In fact, the specific orientation of a RNase molecule can become
crucial for a successful approach to the cell membrane: therefore,
the selection of the most favorable RNase-membrane interaction
patch has been the object of many studies focused especially on
ONC and BS-RNase, but also on RNase 1 and RNase A (12, 121–
123). In particular, the natively dimeric BS-RNase assumes the
most advantageous orientation for its internalization when it
faces both N-termini toward the cell membrane (122), and the
structure of BS-RNase shows that both N-termini actually adopt
the same orientation (19). Furthermore, the G38K-BS-RNase
mutant, being endowed with an additional cationic key-residue
oriented in the same direction of the N-terminus, interacts with
the membrane more strongly and is even more cytotoxic than
the wild type (124, 125). Hence, the the orientation of the basic
charges could also affect the cytotoxic potential of other RNases
and of their oligomers. Other studies showed instead that BS-
RNase approaches the membrane differently from ONC (121)
but similarly to RNase A and RNase 1 (121, 122). RNase 1 in
turn showed itself to be the monomeric variant accompanied
with the highest propensity to be internalized in cells (12).
Moreover, RNase cellular internalization can be considered also
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residue-specific: in fact, wt-ONC is less efficiently internalized
than its so called “R-mutant,” in which all lysine residues but the
two crucial for catalysis are replaced by arginine (126). It has
to be underlined, however, that if the RNase basic net charge
is randomly increased, the advantage represented by a favored
internalization may be counteracted once in the cells by the
RNase affinity increase toward the negatively charged RI (127).
Finally, and interestingly, we note that BS-RNase has a high
binding affinity also toward the extracellular matrix (ECM),
since its cytotoxicity against CHO cells grown in suspension
is quite lower than the one exerted vs. the same adherent cell
subtype (128).
Intracellular Routing of RNases
Once they have entered the cell, RNases must overpass other
obstacles to exert their activity. Some of these issues have been
well-presented in another review contributed by Arnold (129).
The cytotoxic potency of different RNases is certainly due to
optimal cell membrane interaction and endocytic internalization,
but also to their resistance against proteolytic degradation in the
endosomes/lysosomes/trans Golgi and their fruitful release into
the cytosol (118).
Some discordant data are present in literature regarding the
actual internalization mechanism of RNases: in fact, while Haigis
and Raines demonstrated that ONC, RNase A and its G88R
variant are internalized in early endosomes of HeLa and K562
cells by a clathrin- and caveolae-independent mechanism (120),
Rodriguez et al. indicated that Jurkat cells endocytose ONC
through a dynamin-dependent route, presumably following
a clathrin/AP-2-mediated endocytic pathway (130). However,
these controversial data suggest that RNases go through diverse
routes to cross the membrane of different cell lines. In the RNases
routing toward their final cytosolic destination, the first step is
their delivery to early endosomes, while instead the features of the
subsequent intracellular routing steps have not been completely
understood so far. BS-RNase is internalized in endosomal vesicles
either in normal or malignant cells; but only in the latter ones,
where it is cytotoxic, does it reach the Golgi apparatus, i.e.,
the intracellular station, before its cytosolic delivery (131, 132).
In addition, a BS-RNase variant characterized by a C-terminus
engineered with a key-sequence that is useful for its localization
in the endoplasmic reticulum is not cytotoxic because it is unable
to be released in the cytosol to elicit its anti-tumor activity (131).
Furthermore, when two RNase 1 mutants designed to evade RI
were fused with a scFv fragment for human CD7 antigen to be
delivered into leukemic cells, they were able to bind to T cell
surface and to be internalized, but they were not cytotoxic. This
is because they were delivered in the lysosomal compartment
and there degraded. Instead, cytotoxicity was restored when
they were internalized by transfection (133). In contrast, the
human immuno-ErbB2-RNase 1 fusion protein was internalized
in SKBR3 cells, and its direct transfer from endosomes to the
cytosol was demonstrated. In this case, cell death occurred
through apoptosis with an IC50% of 12 nM (134). More recently,
an interesting strategy to intracellularly internalize RNases was
proposed: three cationic amine-reactive linkers were attached to
RNase A, and the stability of these conjugates was pH-dependent.
Therefore, the endocytic vesicles’ acidic environment led to
the release of high cytosolic amounts of RNase A to make its
concentration high enough to overcome the RI binding capacity
and become cytotoxic (135).
However, RNases can have distinct but not always successful
outcomes in several cellular organelles, such as endosomes,
lysosomes, ER and the trans-Golgi network (136). Thus, many
studies have been performed to unveil the intracellular routing
of extracellular RNases once internalized by endocytosis, and the
relative results indicated that diverse RNases, such as ONC or
BS-RNase as well as RNase A, RNase 1, or ANG follow different
cellular pathways within one another, as described or proposed
in several reports (32, 118, 120, 128, 130–132, 135).
Finally, it has to be remembered that the capability to exert
their activity in the nucleus is crucial for some RNases: indeed,
ANG/RNase 5 needs to be enzymatically active (72) but also to
enter the nucleus to exert its fundamental angiogenic activity in
both normal and cancer cells (56, 137). To do so, ANG exploits
its surface loop involving the R31-R32-R33 Arg-triplet, whose
replacement provokes the block of either its nuclear import or
angiogenesis (138). Notably, insertion(s) of nuclear localization
sequence(s) (NLS) involving Arg residues located in loop(s)
present in RNase A or RNase 1 variants make them able to enter
the nucleus and exert angiogenetic (139) or cytotoxic activities
(140, 141), respectively. This evidence suggests that different
RNases located in the same compartment can address their
action against different RNA targets to trigger diverse biological
reactions. Then, considering the human nature of RNase 1, its
nuclear activity becomes advantageous in terms of obtaining
cytotoxic variants devoid of any immunogenicity.
Evasion From the Cytosolic RNase
Inhibitor
As already mentioned, a huge obstacle for an RNase to be actually
active in the cell is represented by the interaction with RI. This
50 kDa protein was firstly extracted from the rat liver while
the human variant was isolated from placenta (142), and its
interaction with RNases was firstly detected with ANG (143).
RI is a negatively charged horseshoe-shaped and leucine-rich
macromolecule that is ubiquitously expressed in almost all cells
(114). RI was considered for many years to be present only
in the cell cytosol, but more recently its presence has been
detected also in mitochondria and nuclei (144). All RI biological
functions have not been completely clarified, but, considering
its numerous cysteine residues, its contribution to the redox
cellular homeostasis has been stated (145). RI can form very tight
complexes with RNase A (146) and with RNase 1 (147), ANG
(148) and EDN (149). RI interacts also with RNase 7 (150) and
is highly conserved in the cells of many mammalian species,
but is present also in non-mammalian ones (151). Most of the
RNase-RI complexes characterized so far are not dissociable
because their Kd values fall into the pico- to femtomolar range
(152). The RNase-RI complex structure(s) explain(s) why RNase
activity is inhibited, being the enzyme moiety caged inside the RI
cavity (153).
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ANG can sterically evade the cytosolic interaction with RI
when it undergoes phosphorylation at some Ser/Thr residues
that are crucial for RI binding (55). In this way, it can be
internalized in the nucleus to exert its angiogenetic activity.
Instead, ONC exceptionally evades or extensively lowers its
affinity for RI because it is devoid of the K7 and G88 key-residues
allowing, in RNase A, the interactions necessary to form the tight
RNase-RI complex. For this reason, ONC can actually display its
remarkable cytotoxicity (154). Hence, site-specific mutagenesis
approaches made also RNases of mammalian origin capable of
evading RI and exerting their cytotoxic potential (155–157). This
could be considered not completely true if we remember that
many years ago, Ledoux found that wt-RNase A can be active
against tumors either in vitro or in vivo (158–160). However, we
must underline that high RNase A doses, not <200 mg/mouse
(159), or concentrations not lower than 2 mg/mL (∼145µM)
in the cell culture medium (160), were used in those cases.
Therefore, even if all RNase A molecules did not enter the cells,
these doses certainly overpassed the cytosolic RI concentration,
that is about 4µM (161). Hence, the exceeding RNase A amount
should be free to exploit RI saturation and exert cytotoxic activity,
in line with that reported by Liu et al. (135). We recall that,
beyond ONC, mammalian BS-RNase is also cytotoxic: indeed,
being natively dimeric, it can sterically evade RI (162). It is
well-known, in fact, that the monomeric BS-RNase derivative,
although retaining its ribonucleolytic activity, definitely loses its
cytotoxicity because it is sequestered by RI (163, 164). Finally,
another way to make potentially active RNases actually cytotoxic
could be to silence the RI action (165), even though the sensitivity
to RI is not the unique factor determining cell cytotoxicity.
To this point, conflicting results support opposite arguments:
certainly, it has been demonstrated that non-cytotoxic RNases are
unable to affect HeLa cells viability also after being deprived of RI
(166). On the contrary, non-covalent artificial dimers of RNase
A, although being RI-sensitive (167), were found to be cytotoxic
against some malignant leukemia cell lines at a concentration
of about 20µg/mL (168), even if they were definitely inactive
against pancreatic cancer cells (125).
Fromwhat has been reported, we can envisage that if an RNase
is induced to oligomerize, and, thus, to be bulkier than its native
monomer, this would augment the charge density of the enzyme
moiety to help its internalization in tumor cells. Furthermore, the
increased steric hindrance would help to evade the RI interaction,
as BS-RNase does. This strategy, and what it is correlated with,
will be presented and discussed in the next chapters.
RNASE OLIGOMERIZATION: A STRATEGY
TO OBTAIN STABLE AND MORE ACTIVE
RNASE DERIVATIVES
Each step necessary to exert their biological action could
represent a huge obstacle for RNases. Hence, point mutations as
well as post-transduction or also in vitro modifications might be
helpful to overcome these barriers. Moreover, in this context, a
controlled induction of protein self-association leading to natural
or artificial RNase oligomers may represent a fruitful strategy
to be promoted or, conversely, underwent by the organism
to obtain RNase derivatives that exert remarkable biological
activities. In line with this argument, RNase or, generally, protein
oligomerization, can occur spontaneously or can be induced also
by the cell environment or by an in vivo context (117, 169, 170).
Again, oligomerization can be provoked artificially in vitro to
obtain a controlled plethora of products that can be characterized
in light of the desired goal.
Covalent Oligomerization of RNases
Artificial oligomerization can be induced to form covalently
linked derivatives upon the reaction of a protein with
bifunctional or multifunctional cross-linkers. In this way, stable
hetero- or homo-oligomers can be produced, but with the
concomitant modification of one or more AA residue(s).
Dimerization or oligomerization can be obtained also with
conditions favoring a spontaneous protein self-association.
Again, the cross-linking of the subunits of a protein can occur
spontaneously or in response to a cell signal, in membrane
proteins or cell factors upon undergoing photochemical events,
phosphorylation, apo/holo transitions, or even other post-
transduction modifications. To date, within mammalian RNases,
only BS-RNase is known to be a native homo-dimer thanks to
the formation of two antiparallel disulfides involving the Cys31
residue of one subunit with the Cys32 of the other, and vice-
versa (18). These two residues are instead different from cysteine
in all other known RNases. Therefore, many strategies have
been followed to induce a RNase to dimerize or oligomerize by
forcing it to react with the appropriate cross-linking reagent(s).
It should be taken into account, however, that any chemical
modification can somehow modify the properties of native
RNase and, thus, might negatively affect its biological activities.
Hence, a balance between desired modifications and an excessive
unwanted affection of the native properties is mandatory to
obtain derivatives accompanied with fruitful enzymatic and
biological activities.
Covalently Linked Homo-Oligomeric RNases and
Their Biological Activity
RNases can be artificially associated by exploiting cross-linking
reactions with various bifunctional or multifunctional reagents.
The most used cross-linkers are mentioned below. This involves
especially RNase A and RNase 1, and will be accompanied
with the description of the positive or negative rebounds on
the relative catalytic and/or the antitumor activities of the
products obtained:
(i) Diimidoesters or dialdehydes (Figures 1A–C), i.e.,
bifunctional cross-linkers, can react with the Lys residues
of a protein. These reagents display two terminal reactive
groups separated by a variable number of unreactive
methylene (–(CH2)n-) spacers. As concerns RNase
A, its reactions with dimethyl-adipimidate, dimethyl-
pimelimidate or, especially, dimethyl-suberimidate, i.e.,
reagents displaying spacers with different “n” values
(Figure 1A), allow differently sized stable dimers or
oligomers (171, 178) to be formed, often accompanied
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FIGURE 1 | Chemical cross-linkers mostly used with RNases and main immuno-RNases oligomeric derivatives. (A) Diimidoesters (171); (B) Mechanism of reaction of
RNases with diimidoesters; (C) glutaraldehyde; (D) trifunctional maleimide (172); (E) divinylsulfone (DVS) (173); (F) difluorodinitrobenzene (DFDNB) (174); (G)
Immuno-HP-RNase-heterodimer: the HP moiety (black) and the Erb2 one (gray) (175); (H) HP-RNase diabody (176); (I) Immuno-ONC-heterodimer (177); (J) ONC
(rap)-diabody (177).
with higher enzymatic activity than the native monomer.
Cross-linkers are advantageous to produce protein homo-
oligomers or, alternatively, a cationized and thus more
cytotoxic complex, by adding bulky amines or polyamines
through the covalent mediation of the diimidoester (179–
181). The cross-linking can be reversible if the spacer
contains a disulfide bond that becomes scissile once the
cytosolic reducing environment is reached (182). The
reactivity of the Lys nucleophilic residues for the two imides
of the cross-linker (Figure 1B) can be more efficiently
controlled than with dialdehydes like glutaraldehyde
(Figure 1C), and this allows the processed protein to
maintain its overall charge unmodified (171, 180). An
important undesired limitation is represented by the
susceptibility to the cross-linker of the active site Lys
residue unless it is not protected by phosphate, thus
driving toward a percentage of inactive products (171, 183).
However, upon properly tuning the reaction conditions,
amounts of RNase A dimers characterized by enzymatic
and cytotoxic activities definitely higher than native
RNase A can be produced (184, 185). Again, beyond 20%
yield of active RNase A dimers, dimethyl-suberimidate
(Figure 1B) allowed the formation of amounts of covalently
linked trimers and traces of higher-order oligomers, all
characterized by a relevant cytotoxic activity against cells
of the uterus cervix squamous carcinoma (183). Beyond
polyamines, RNases can be complexed also with differently
sized PEG moieties: indeed, a RNase 1 PEG-derivative
is known to inhibit tumor growth in mice (186), while
PEG-conjugated RNase A oligomers are cytotoxic against
transplanted melanoma in mice as well (187).
(ii) To obtain active RNase oligomers, the bifunctional N-
substituted maleimide derivatives displaying spacers of
variable length are certainly useful (182). These reagents
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induce the cross-linking between a free Cys sulfhydryl
and the maleimide to form a reversible adduct if the
spacer contains a scissile disulfide bond. The presence of a
protein free –SH group is mandatory to make this cross-
linking productive. Unfortunately, RNases do not display
free cysteines, and, consequently, the reaction can occur
only upon introducing a free Cys residue upon mutagenesis
(172). Maleimides can also be trifunctional (Figure 1D), or
even more, in this way producing covalently linked trimers
and/or larger oligomers. Indeed, the group led by Raines
succeeded in obtaining many trimers by coupling cysteine-
free RNase A, RNase 1, BS-RNase, or ONC mutants with
tris(N-maleimidoethyl)amine (172). For all these RNases
except for ONC, many mutants displaying a Cys in spite
of the Gly88 residue were produced. The mutation of G88
of the wild type is required because this residue allows
the proper accommodation of a RNase molecule into the
RI cavity to form the already mentioned tight RNase-RI
complex (152, 153). Instead, since ONC lacks Gly88, the
S72C-ONC mutant was produced to allow the formation
of the trimer upon cross-linking the protein with the
trifunctional maleimide. All RNase trimeric adducts but
the ONC one increased their antitumor activity, either
in vitro or in mice, with respect to their inactive or less
active wt-monomers. Only the trimeric S72C-ONC showed
instead to be less cytotoxic than its definitely active wt-
ONC monomer (172). However, the advantage to obtain a
bulky ONC trimeric derivative resides on its very probable
steric inability to be filtered by the kidneys’ glomeruli
and, as a consequence, on its increased circulating half-
life. Indeed, this may represent a crucial advantage in
the perspective to use these products in cancer therapy,
considering that the monomeric wt-ONC displayed renal
toxicity in vivo, although this undesired effect was reversible
upon discontinuing the treatment (188).
(iii) Zero-length dimerization: RNases dimers or oligomers
can be formed also upon interaction with carbodiimides
(R1-N=C=C-R
+
2 ), i.e., dehydrating molecules, such as
N-(3-Dimethylaminoisopropyl)-N′-ethylcarbodiimide
(EDC), that can induce the formation of a “zero-length”
dimer(s) or larger oligomer(s) characterized by isopeptide
bond(s) involving the side chain of the amino group of
Lys and the carboxylate group of Asp or Glu residues
(189). These reagents can covalently fix previously
formed oligomeric aggregates and contemporarily avoid
unwanted charge modifications or insertions of chemicals
in the protein complex. Supramolecular RNase zero-
length adducts can be produced also by heating the
protein up to 85◦C under vacuum (190). This method
allowed RNase A to form novel isopeptide bonds
between Lys and Glu or Asp residues upon inducing
heat-vacuum dehydration. This condensation reaction
affects principally, but not exclusively, the RNase A E9
and K66 residues (190, 191). However, these derivatives
showed a definitively reduced enzymatic activity and
inactivity against cancer cells unless they were strongly
cationized with polyspermine. This is probably due
to the excessive number, at least three, of the affected
Lys residues and, thus, by the scarce specificity of the
cross-linking reaction that drives toward a mixture of
heterogeneous products (191). However, it must be
mentioned that the strong cationization allowed the other
RNase adducts to gain cytotoxicity but also aspermatogenic
effects (181, 192–194).
(iv) More recently, oligomers have been produced also upon
mixing at 37◦C RNase A with metallic derivatives
commonly used as chemotherapeutic agents, such as
cisplatin, or also carbo- or oxaliplatin (195, 196). The yield
of RNase A-cisplatin oligomers remarkably increases with
the cisplatin/protein ratio (195), while with the other Pt
adduct yields are definitely lower (196). Unfortunately,
these adducts are endowed with scarce ribonucleolytic
activity and lack cytotoxicity principally because the
catalytic H119 residue is directly involved in the linking
with the metallic moiety (195, 196). Hence, this result
helps to explain why cisplatin and/or similar adducts
display a reduced efficacy and undesired side-effects in
therapy: in fact, this is because they very probably
affect proteins, such as here RNase A, or in vivo serum
albumin as well, at a higher extent than the desired
DNA target.
(v) RNases can be cross-linked also by using the bi-functional
cross-linkers divinyl-sulfone (DVS, Figure 1E) or
difluorodinitrobenzene (DFDNB, Figure 1F), which
are specific for His or Lys residues, respectively
(173, 174). These cross-linkers lack spacers and can
cross-link only residues residing very close to each
other, or they can covalently stabilize preformed
oligomers. Indeed, they are extremely useful for
characterizing the mechanism of formation of non-
covalent supramolecular structures produced by BS-RNase,
RNase A or ONC (173, 197–200), but they can be
used only for analytical purposes because they totally
inactivate the resulting products by involving active
site residues.
Covalently Linked or Fusion RNases
Hetero-Oligomers and Their Biological Activities
(i) Asymmetric bifunctional reagents are certainly useful in
overcoming the lack of protein-free Cys residues: in fact,
they can covalently link antibodies, or parts of them
(light/heavy chains), with proteins, protein domains, toxins
or whatever displays biological interest (Figures 1G,I). They
can be, on one side, maleimides or succinimides sometimes
displaying dithio-derivatives in the spacers, combined in
the other terminus with imidoesters, diones, thiones, or 2-
iminothiolane. One reagent often used to achieve a covalent
hetero-dimerization is 1-(3-((2,5-Dioxopyrrolidinyl)oxy-
carbonyl)phenyl)-1H-pyrrole-2,5-dione (MBS), but many
others are available (201). Some of them have been
tested with proteins different from RNases (202), but
asymmetric reagents have been used to form active hetero-
adducts involving RNases as well: in fact, ONC displayed
a remarkable antitumor activity against breast cancer or
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brain glioma both in vitro or in mice upon its chemical
conjugation with Trop-2 (or EGP-1), or, alternatively, with
a chlorotoxin (203, 204). Again, strong specific anti-tumor
effects exerted by both LL2 or anti-CD22 monoclonal
antibodies covalently linked to ONC significantly increased
the life span of animals displaying non-Hodgkin B-cell
lymphoma (205). Some other chemically cross-linked EGF-
RNase or Immuno-RNase tumoricidal adducts have been
produced since the 90s with RNase A (206, 207) or RNase
1 (208). The list of all the mentioned heterocomplexes are
reported in Table 1 together with the ones obtained as
immuno-fusion products that are discussed hereafter.
(ii) Alternatively, protein engineering permits cloning and
expressing fusion homo- or hetero-fusion dimers as well
as fusion immuno-protein conjugates (Figures 1G–J). The
cDNA encoding the desired RNase is fused with genes of
heavy or light single-chain antibodies. The same strategy
can be followed with diabodies (Figures 1H,J), which are
non-covalent dimers of single chain antibody fragments
(scFv) consisting of variable regions of heavy and light
chains (VH and VL) connected by a small peptide linker
(175, 201). If desired, additional peptide spacers of various
lengths and nature can be inserted between the proteins
(210, 218, 222). In this way, a natural covalent link binds
the two proteins, thus permitting the expression of the
complete adduct without requiring subsequent chemical
modifications. Again, in some cases, as it is for diabodies, the
hetero-dimeric immune-RNase adduct has been considered
as a new entity that can be further dimerized to form a more
active tetramer, as it was performed with both RNase 1 and
ONC (Figures 1H,J) (176, 177, 216). Additionally, a fusion
protein composed of two ONC molecules, each fused to the
N-terminus of the VL of an anti-CD74 humanized antibody,
was demonstrated to exert an excellent therapeutic efficacy
against CD74+ tumors either in vitro or in vivo (217).
Following these strategies, several Immuno-RNase or
Immunotoxin-RNase complexes have been produced and
used as anticancer agents (175, 228) also with RNase A.
Instead, the group of D’Alessio and De Lorenzo chose to
couple human RNase 1 with the human anti-ErbB2 (Figure 1G)
(175, 210, 211, 229). The resulting heterodimeric ERB-hRNase
adducts showed to be definitely more cytotoxic against breast
cancer and induced less resistance and cardiotoxicity than
a humanized anti-ErbB2 monoclonal antibody used as a
chemotherapeutic agent (175). Furthermore, the tetrameric
adduct, i.e., the dimer of the hetero-dimer, called ERB-HHP2-
RNase, was displayed to be even more cytotoxic than the simple
ERB-hRNase adduct (176). Again, some RNase 1 mutants
designed to evade RI, and fused to a scFv fragment specific for
CD7, reduced the viability of human T leukemic cells (133). More
recently, an anti-nucleolin(NCL)-immunoRNase 1 derivative
was displayed to be active against triple-negative breast cancer
not responding to treatments available so far (212).
The protein-fusion technique has been applied also to
ONC to conjugate and express it with many diverse adducts
(Figures 1I,J), such as various antibody fragments, human serum
albumin, dengue virus-derived peptide, and more recently with
the N-terminal domain of transferrin (177, 216, 218, 219, 221,
230). All these adducts displayed augmented cytotoxicity in
vitro against many cancer cells, and in some cases also in mice
(177, 218). This augmented activity was often accompanied with
a lower propensity to undergo renal filtration, as indicated by
the results obtained with membranes mimicking the kidney
glomerular barrier. Then, another crucial advantage offered by
human Immuno-RNases over microbial or plant immunotoxins
is the lack of immunogenicity or of non-specific binding and
toxicity that usually also affects normal cells. These undesired
events drove in some cases even toward fatal events during
clinical trials (231). Indeed, De Lorenzo and D’Alessio clarified
that the immune-RNase 1 fusion proteins were not only non-
toxic outside the tumor cells but also non-immunogenic (228).
Again, as reported in Table 1, the protein-fusion strategy against
cancer has been used many other times with RNase 1 (213–215)
and ONC (220), but also with BS-RNase (226) and EDN (225),
producing cytotoxic derivatives. Also Immuno-ANG derivatives
have been produced, and the effects on their cytotoxic activity
induced by proper ANG mutations (223) or by different linkers
introduced in the supramolecular adducts have been compared
(222). Again, ANG was driven also toward a diabody-conjugated
dimer that was revealed to be definitely more cytotoxic than the
monomer (224). Notably, bacterial barnase and fungal RNase T1
have also been derivatized as immunotoxins to become capable of
being internalized in cancer cells and exert a remarkable cytotoxic
activity (87–89, 227). Finally, in the last decade, RNase A has
also been dimerized by cloning and expressing it as a tandem
derivative in this way:
Monomer1-C-term—peptide linker—N-term-Monomer2
Contrarily to the inactive monomer, this fusion-stabilized
RNase A derivative became definitely cytotoxic against K562
human leukemia cells (209), although it was revealed to be 1:1
complexed with RI (232). This apparently contradictory result
could be explained by considering that each RNase A fusion
moiety contains one active site, and one of them could be
oriented in a way to actually exert its catalytic and cytotoxic
actions. To this regard, we underline that the structure of the
fusion RNase A—RNase A derivative (see Figure 3B) is not in
contrast with this explanation (209, 232). All the fusion-produced
immuno-derivatives here mentioned are listed in Table 1. Again,
many reviews have been focused on the selective cytotoxic action
of Immuno-RNases against tumor cells (108, 175, 238), as it is for
the recent and updated one of Jordaan et al. (239).
Non-covalent RNase Oligomers
Protein oligomerization can also occur non-covalently,
either as a natural or an artificial event: indeed, natively
monomeric proteins can undergo dimerization or an even
larger oligomerization degree. This may occur as a sort of
post-translational event that can switch between active and
inactive products. Many reports analyzed the features of
this event involving many proteins (169, 170, 240). In the
following paragraphs, we will instead focus our attention on
the mechanism mainly followed by RNases to self-associate
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Ligand = linker/spacer Diabody Y/N Cell/target and/or human cancer
counteracted
References
Transferrin(Tf)-RNase A Chemical Peptide N Tf-Receptor Leukemia (108)
Anti-TfR-RNase A Chemical Monoclonal Antibody N Tf-Receptor
Glioma
(108)
scFv CD5-RNase A Chemical Succinimidyl-pyridyl-thiopropionate
(SPDP)
N K562 and Jurkat-Leukemia;
U251-glioblastoma cell lines
(206)
EGF-RNase A Chemical Succinimidyl-pyridyl-thiopropionate
(SPDP) and 2-iminothiolane (2-IT)
N Many squamous carcinoma and
breast cancer cell lines
(207)
RNase A-RNase A tandem Fusion (SG)3S/SGRSGRSG/GPnG N K-562 leukemia cells (209)
EGF-RNase 1 Chemical Succinimidyl-pyridyl-thiopropionate
(SPDP) and 2-iminothiolane (2-IT)
N Many cancer cell lines (208)
scFv-ErbB2-RNase 1 Fusion GSPEFM peptide N SKBR3 and MDA-MB453 breast
cancer cells;
A431 epidermal carcinoma cells
(210)
scFv ERB-HHP2-RNase1 Fusion SS(G4S)2GGS linker
AAASGGPEGGS junction peptides
N SKBR3 and MDA-MB453 breast
cancer cells;
A431 epidermal carcinoma cells
(176)
scFv-Erb-hcAb-RNase 1 Fusion AAASGGPEGGS peptide linker N SKBR3 and MDA-MB453 breast
cancer cells;
A431 epidermal carcinoma cells
(211)
AntiNCL scFv4LB5-RNase1 Fusion SGGGGSGGGGSGGS linker
AAASGGPEGGS spacer
N MDA-MB-231/436, BT549 breast
cancer cells;
SW 620 colon adenocarcinoma cells;
In vivo nude mice MDA-MB-231 triple
negative breast cancer
(212)
FGF Nterm-RNase 1 Fusion LPALPEDGGS peptide linker N Many cell lines (213)





Fusion AAASSG peptide linker N Karpas-299 Lymphoma cell line
HEK 293T human embryo
kidney cells
(215)










N Glioma U251 and SHG-44 cells (204)
scFv LL2-ONC Chemical Succinimidyl-pyridyl-thiopropionate
(SPDP)
N Daudi lymphoma in mice (205)





Anti-EGFR-scFv IZI08-ONC Fusion GGGGS or (G4S)3 peptides Y A431/Raji/HNO and FaDu
oro-pharyngeal/CAL27 tongue/MCF7
breast cell lines +
In vivo A431 Nude mice
(177)
2L-ONC-hLL1-γ4P (S228P) Fusion (G4S)3 peptide linker N Daudi/Raji and MC/CAR lymphocytes




N HT29 Colorectal carcinoma and







A431 epidermal, and MCF7 breast
carcinoma cells
(219)






Fusion (G4S)3 peptide linker N HepG2 hepatocarcinoma
HeLa cervix carcinoma cell lines
(221)
(Continued)
Frontiers in Immunology | www.frontiersin.org 10 November 2019 | Volume 10 | Article 2626
Gotte and Menegazzi Antitumor RNase Oligomers























Fusion G85/86R and/or Q117G mutations
H22-fragm, linker not specif





scFv MLT 7-ANG dimer
Fusion (G4S)3 peptide linker-MJ 7 direct
linking with MLT 7
Y Daudi/Jurkat/Raji cells and HuT 102
cutaneous lymphoma cells
(224)





Fusion KDEL BS-elongation peptide +
N-term DT Linker





Fusion HisTag/linker not specified N SW1222 colon carcinoma gpA33
positive cells
HT29 colorectal and MCF-7 breast
gpA33 negative cells
(227)
scFv 4D5-dibarnase Fusion Peptide + HisTag N DNA fragmentation/apoptosis many
cell lines
(87)





Fusion Peptide + HisTag N Endosomes/lysosomes
Ovarian and breast carcinoma
SKOV-3 and BT-474 cells
(89)
FIGURE 2 | Scheme for the 3D-DS protein association mechanism. The
closed interface present in the native monomer and reconstituted in the
domain-swapped dimer, and the open interface(s) forming only in the dimer
are indicated (241), as well as the composite functional unit (FU) (235) of the
dimer inside the dashed line.
without being covalently cross-linked, i.e., the one called three
dimensional domain swapping (3D-DS), whose schematic
picture is shown in Figure 2.
RNases and the Oligomerization Through
Three-Dimensional Domain-Swapping (3D-DS)
The non-covalent self-association of RNases is mainly ascribable
to the 3D-DS mechanism, as reported in Table 2. Firstly defined
and described by Eisenberg et al. (241, 242), and affecting
many proteins (235, 243, 244), this mechanism has been deeply
analyzed also by many other scientists (241, 244–247). 3D-DS
partially violates the Anfinsen dogma which states that the AA
sequence induces a protein to find a unique folding (10): in
fact, the flexible loops of a protein (in particular, for RNase
A, residues 16–22 and 112–115) can instead adopt variable
conformations, thus occupying more than one energy minimum
(241). This allows the domains linked to the protein flexible
parts to adopt different orientations and to undergo a reciprocal
exchange of a protomer domain with the equivalent domain
of an adjacent subunit. Therefore, a non-covalent dimer, or
even larger oligomers, if more than a single flexible loop is
present, can be formed (235, 243). The domain detached from the
native monomer can reconstitute the native protomer contacts in
each composite, functional unit (FU) of the oligomer (Figure 2)
(235). The novel FU overlaps the native monomer, except for
an additional interface(s), whose conformation depend(s) to
each particular protein, and that is/are absent in the native
monomer (241). The domains involved in 3D-DS are often the
protein N- or C-termini, or both, as it is for some RNases
(235, 243). Oligomerization is often accompanied in RNases
with an increase of their enzymatic and biological activities, or,
moreover, with new properties absent in the native monomer.
Notably, the 3D-DSmechanism is shared bymany other proteins,
like for example cytochrome C (248), and above all by several
amyloidogenic proteins, such as human prion protein, cystatin-
C or also β2-microglobulin, all self-associating through 3D-DS
(249–252). Except for ECP/RNase 3 (46), all known RNases are
unable to undergo amyloidosis, although RNase A displays many
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TABLE 2 | List of the most important secreted RNases that spontaneously oligomerize.
Secreted RNase Oligomers 3D-DS* mechanism Cross-linked oligomers Cytotoxic activity
RNase A Dimers/Trimers/Tetramers up to
Tetradecamers traces
Y: N + C-swap Native with bifunctional linkers




Y: N + C swap Natural S-S bonds Yes
RNase 1 Dimers Y: N-swap
in mutants
Mutants with S-S bonds
(HHP/HHP2-RNase 1)
Oligomers: Yes
ANG Not detected Not detected Only Immuno-derivatives Oligomers: Yes
ONC Dimer Y: N-swap Only in Immunoderivatives Monomer and Dimer:
Yes
Barnase Trimer Y: N-swap Immunoderivative Yes
Binase (dimeric) Only the native dimer Not detected. Not detected Yes
RNase T1 Dimer mutant Y Immunoderivative Oligomeric: Yes
*3D-DS, three-dimensional domain swapping.
amyloid-prone segments. However, the presence of 3D-DS was
not proven in ECP (253). Indeed, it is worth noting that residue(s)
insertion(s) was incurred by the RNase A loops, allowing the
3D-DS to occur make it capable of forming amyloid-like domain-
swapped fibrils (254, 255).
The non-covalent aggregation has been known to occur in
RNase A and BS-RNase since the 60s (256–258), affecting the
catalytic activity against RNA substrates. The 3D-DS involvement
had already been hypothesized in 1962 by Moore et al. on the
basis of the characterization of RNase S deriving from RNase A
limited proteolysis that cleaves the N-terminal domain (residues
1–20) from the protein core (259, 260). RNase A aggregation was
therefore already ascribed to a reciprocal exchange of the protein
N-termini consequent to their detachment from the protein core
(256). The actual presence of 3D-DS in RNases was then detected
for BS-RNase only in 1993 by Mazzarella et al., while for RNase A
in 1998 by Liu et al. (19, 233).
In the next paragraphs we list and discuss the main features
of the domain-swapped dimers and oligomers of various
pancreatic-type RNases, above all RNase A, BS-RNase and RNase
1, and recently also ONC, to highlight the related biological
consequences. We start with RNase A, but in each paragraph
comparisons within different RNase variants will be present.
RNase A
Natively monomeric, 13.7 kDa RNase A (Figure 3A) can
non-covalently self-associate by interacting with the substrate
(261), but it can also oligomerize upon being subjected to
lyophilization from 40% aqueous acetic acid solutions (256)
or to thermal incubations in different solvents at very high
protein concentration (262). Following these two protocols,
RNase A produces domain-swapped dimers, trimers, and larger
oligomers (115, 198, 235, 237). Oligomerization occurs through
the aforementioned 3D-DSmechanism involving both N- and/or
C-terminal domains of the protein (115, 235), thus producing
different relative amounts of N- or C-swapped oligomers as
a function of the particular protocol applied (256). Oligomers
can be separated with cation-exchange chromatography, being
the C-swapped species endowed with a higher basic charge
exposure than the N-swapped ones (263). NMR showed that
RNase A is chiefly denatured except for disulphides in 40% acetic
acid, while it refolds properly, with the exception of the 3D-
DS-inducing flexible loops only when, after lyophilization, it is
redissolved in a “benign” buffer, such as phosphate (264). This
permits the formation of many different RNase A oligomers, up
to traces of tetradecamers (265). The structures of the RNase
A N- and C-termini-swapped dimers (called N-dimer or ND
and C-dimer or CD, respectively), and of a cyclic C-swapped
trimer, CT, have been solved (Figures 3C,D,F) (233, 234, 236).
Additionally, models based on experimental data have been built
for a N + C-swapped-trimer, i.e., displaying the swapping of
both enzyme termini (NCT, Figure 3E), and for many other
N + C-swapped tetramers (Figures 3G–J) or larger multimers
(197, 235, 237). The most abundant species detectable is certainly
the C-dimer that approaches 20% yield, while its amount deriving
from thermal incubations is lower (197, 262). DVS or DFDNB
(Figures 1E,F) crosslinking analysis confirmed that the protein
self-associates through 3D-DS involving both RNase AN- and/or
C-termini in all the oligomers, up to hexamers, analyzed (197,
198). The structural determinants governing RNase A 3D-DS
oligomerization have been deeply investigated (266). In detail,
the polarity of both RNase A N- and C-termini affects both
the swapping propensity and the oligomers’ stability (267),
while either reducing conditions or deamidation events affecting
many Asn residues reduce the tendency of RNase A aggregation
through 3D-DS (268, 269). Importantly, the cis configuration
of the X-Pro114 peptide bond present in the loop preceding
the C-terminus of RNase A, RNase 1 or also BS-RNase hinders
the tendency of the same terminus to be swapped (266, 270,
271). Consequently, harsh conditions are required to switch the
mentioned bond from cis to trans and let the formation of
remarkable amounts of RNase A C-dimer (262). In this context,
it is quite surprising that about 20% of RNase A C-dimer was
detected in the endoplasmic reticulum of pancreatic exocrine
cells, although subsequently the dimer failed to be secreted (272).
Also, glycosilation can hinder RNase 3D-DS self-association, as
was demonstrated by the Asn34 N-glycosilated RNase A form
called RNase B (16). Many reports indicate the actual reciprocal
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FIGURE 3 | Structures of RNase A, of its tandem dimer, and of its domain-swapped oligomers. (A) RNase A; (B) covalent tandem dimer (232); (C) crystal structure of
the N-swapped dimer, ND (pdb 1A2W) (233); (D) crystal structure of the C-swapped dimer, CD (pdb 1F0V) (234); (E) N + C-swapped trimer model, NCT
(197, 235, 236); (F) crystal structure of the totally C-swapped cyclic trimer, CT (pdb 1JS0) (236); (G) N + C + N-tetramer linear model (197, 235); (H) C + N +
C-tetramer linear model (197, 235), (I) N + C + N-tetramer bent model (237); (J) N + C + C + C-tetramer model (235).
influence of the N- and C-termini in their swapping behavior (16,
267, 273, 274), in line with RNase S (259): indeed, this derivative
dimerizes upon acidic lyophilization, but less than RNase A and
obviously only through the swapping of its C-terminus (275).
All 3D-DS RNase A oligomers increase their enzymatic
activity against ds-RNA substrates, or vs. DNA:RNA hybrids,
with respect to the native monomer (258, 263): the increase is
directly proportional to the size of the oligomers, and moreover,
within the same type of oligomer, i.e., within ND vs. CD, or NCT
vs. CT, etc. (see Figures 3C–J), the highest enzymatic activity
is displayed by the species containing more C-swaps than N-
swaps, because the former species expose a higher basic charge
density than the latter ones (263). The antitumor activity of the
oligomers has beenmeasured too, obtaining controversial results:
a relevant activity always increasing with the basic charge density
of the oligomers was displayed against leukemia cells in vitro and
in vivo when human melanoma cells were transplanted in nude
mice (116, 168). Moreover, in similar in vivo experiments, this
antitumor activity slightly increased when RNase A oligomers
were conjugated with PEG (187). In those cases, both free and
PEG-conjugated RNase A oligomers were devoid of embryotoxic
activity (168, 187). Conversely, the same RNase A oligomers
were not active against two human pancreatic tumor cell lines
(125). However, the actual antitumor activity of the RNase A
oligomers is debated because the two RNase A dimers are known
to interact with RI, although with a 1:1 stoichiometry, like
the aforementioned tandem RNAse A-RNase A fusion dimer
(Figure 3B) that was displayed to be cytotoxic (167, 232). It must
be underlined, however, that Wang et al. recently reported that
RNase A, differently from RNase 1 and ANG, can induce cell
proliferation ascribable to an extracellular RNase A interaction
with the epidermal growth factor receptor (EGFR), in this way
counteracting cytotoxicity as well (276). Hence, from what has
been reported, the evaluation of the actual antitumor potential of
RNase A species certainly deserves further investigation.
BS-RNase
As mentioned, BS-RNase is the unique natively homo-dimeric
member of the pancreatic-type RNase superfamily because of
the two antiparallel disulfides linking the Cys31 residue of one
subunit and the Cys32 of the other, and vice-versa (277). These
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two residues are absent in other RNases. However, each BS-
RNase subunit is composed of 124 AA residues and displays
82% sequence identity with RNase A (17). Interestingly, native
BS-RNase is an equilibrium mixture between two isoforms
(Figures 4A,B), one of which (∼70%) is characterized by the
swapping of its N-termini and is represented as M×M (panel B),
while the other (∼30%) is unswapped and named M=M (panel
A) (278), given that only the two inter-chain C31-C32/C32-
C31 disulfides permit the dimer formation. This M×M/M=M
equilibrium has been deeply investigated (282) and partially
affects the catalytic activity of the enzyme (278). The role of
the inter-subunit disulfides has also been analyzed (283, 284),
as well as the one of the hinge loop connecting the N-terminus
with the protein core. In addition, P19 and L28, as well as R80
residues, have been shown to influence the M=M vs. M×M
equilibrium (285–287).
The ribonucleolytic activity of the enzymes present in the
bovine seminal fluids was firstly described by D’Alessio and
Leone in 1963 (288). The responsible agent for this activity was
discovered to be BS-RNase, that is definitely more basic and
more active against ds-RNA adducts than RNase A (289). This
is true also after monomerizing the enzyme by the reduction of
the two inter-subunit disulfides (290), thus confirming that the
basic charge density, and not the dimeric nature per se, is crucial
for a RNase to be active against ds-RNA substrates. Moreover, as
reported before, BS-RNase exerts a remarkable antitumor activity
(162, 291, 292), together with immunosuppressive, embryotoxic
and aspermatogenic effects (73, 75–77). Cytotoxicity is selectively
addressed only against malignant cells, also of human origin
(125, 293, 294), and is ascribable only to the N-swapped M×M
isoform, while neither M=M nor the wt-monomeric derivative
are active (162, 164). This feature has been ascribed to the ability
of only M×M to evade cellular RI: in fact, the cytosolic reducing
environment, although breaking the two inter-subunit BS-RNase
disulfides, does not monomerize the M×M isoform, whose
dimericity survives, although as a non-covalent dimer (NCD),
for a sufficient time to exert its cytotoxic action. The unswapped
M=M isoform instead undergoes monomerization upon losing
the two mentioned disulfides and becomes therefore susceptible
to the RI blockage (164). The crystal structures of the M=M,
M×M (Figures 4A,B), and NCD isoforms of BS-RNase, as well
as of the monomeric derivative, have been solved, in this way
clarifying crucial structural features that govern the possibility of
this enzyme to exert its biological activities (19, 279, 295, 296).
FIGURE 4 | Structures of BS-RNase and of its tetrameric derivatives. (A) BS-RNase unswapped native dimer isoform, M=M, about 30% of the total (278, 279);
(B) N-swapped native dimer isoform, M×M, about 70% of the total (19, 278); (C) totally N-swapped cyclic tetramer model plus schematic model (280); (D) N + C +
N-swapped tetramer (199); (E) PALQ-BS RNase mutant non-covalent dimer and (F) its comparison with the N-swapped BS-RNase wild type (281).
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Importantly, the M×M isoform does not vary its conformation
upon losing its inter-subunit disulfides and forms NCD only if
the P19 and L28 are conserved, because these residues allowNCD
to maintain the capability to evade RI (see Figures 4E,F). The
P19 and L28 mutations induce instead a dramatic variation in
the reciprocal orientation of the two subunits that renders the
mutated NCD variant inactive because it becomes susceptible
to RI (281). However, mutants of the monomeric BS-RNase
derivative designed to evade RI exerted a 30-fold higher cytotoxic
activity than the wild-type dimer (292).
As well as RNase A (269, 297), BS-RNase easily undergoes
Asn67-to-Asp deamidation, an event that is even quicker than
for the pancreatic variant (298). However, the acquired negative
charge of Asp67 does not affect its cytotoxicity. Additionally,
many efforts have been performed to increase the RNase A/BS-
RNase similarity to make also the pancreatic variant endowed
with antitumor activity. To this end, dimerizing RNase A
variants built through the introduction of the K31C/S32C
mutations, in addition to others, was revealed to exert relevant
antitumor action against malignant fibroblasts (299, 300),
while the cytotoxicity of an engineered RNase A/BS-RNase
hybrid displaying a N-swapped dimeric structure was not
measured (301).
Interestingly, BS-RNase can also be induced to self-associate
upon acetic acid lyophilization. In this way, tetramers, hexamers
and even larger oligomers can be formed: two different tetramers
forming through the swapping only of their N-termini were
hypothesized and modeled by Mazzarella et al. (Figure 4C)
(280), while more recently it has been demonstrated that BS-
RNase can swap also its C-termini, as RNase A does. The C-
termini swapping can occur either in the native dimer, to form
a N + C + N-swapped tetramer (Figure 4D) (199), or also
involve the BS-RNase monomeric derivative to produce a C-
swapped dimer structurally similar, but not identical, to the
RNase A CD (302). Importantly, BS-RNase oligomers also display
enzymatic and cytotoxic activities higher than the native dimer;
again, both activities increase with the size of the oligomers
and, consequently, with their basic charge density (199). To this
regard, many structural, enzymatic and antitumor features of
RNase A and BS-RNase oligomeric species are compared and
discussed in (117).
RNase 1 or HP-RNase
Human pancreatic (HP) RNase 1 (Figure 5A) is natively
monomeric, but, being 128 AA residues long, it displays a C-
terminus elongation of four residues with respect to its bovine
homolog RNase A, and it is more basic than it (266, 305). This
elongation does not affect RNase 1 stability and reduces only
slightly its enzymatic activity (306). Moreover, this variant is
definitely more active than RNase A vs. ds-RNA substrates (12),
FIGURE 5 | Structures of the human pancreatic RNase 1 and of the dimers of two of its mutants. (A) HP-RNase 1; (B) crystal structure of the N-swapped dimer of
PM8 (PM5 + P101Q) mutant (pdb 1H8X) (303); (C) des-N-swapped dimer (304).
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reaching a maximal value at pH 7.3. This pH is very close to
the one of the blood and definitely higher than 6.5, the value
under which RNase A exerts its maximal activity (12). Therefore,
considering the high basicity of its native state, RNase 1 has been
mutated to insert, as well as in RNase A (299), two 31 + 32
cysteine residues to make it dimerize similarly to BS-RNase: these
mutants, named HHP-RNases, displayed a remarkable antitumor
activity against several types of malignant cell lines, among which
cells from neuroblastoma and rhabdomyosarcoma showed the
highest sensibility (307). Indeed, the RNase 1 variant displaying
the Cys31 + 32 couple plus the N28L/N34K/E111G mutations,
and called HHP2-RNase, exerted a quite high antitumor activity
against human thyroid carcinoma-derived cell lines and in vivo
when malignant cells were transplanted into nude mice (308).
Cytotoxicity was exerted by both swapped and unswapped
isomers, contrarily to BS-RNase, and this result was ascribed to
the stabilization effect of both the hinge loop and the Leu28
side chain in terms of maintaining the two Cys31/32 residues
close to each other (309). More recently, other different Cys31/32
cytotoxic dimeric mutants have been engineered to evade RI,
and they were displayed to exert a relevant cytotoxic activity as
well (310).
Other RNase 1 mutants able to swap their N-termini have
been produced: five-residue mutant (PM5) that makes the RNase
1 N-terminal edge identical to BS-RNase displayed a higher
stability than the wild type (311). Moreover, an additional
P101Q mutation introduced in this variant allowed RNase
1 to spontaneously dimerize through 3D-DS thanks to the
formation of four novel inter-subunits H-bonds (Figure 5B).
This additional mutation permits also stacking interactions
between the β-sheets of each protomer to be gained, similarly
to what occurs in the RNase A ND (303). Hence, this
RNase 1 N-swapped dimer, called PM8, combines the structural
determinants of BS-RNase (five mutations in the N-terminus,
PM5) with the crucial role of Gln101 detected in the RNase
A N-dimer (233, 312). However, the structure of this dimer
(303) is quite different from both BS-RNase M×M isoform
because the Cys31-32 disulfides are absent (19, 233). Again,
deletions suffered by the loop connecting the N-terminus to the
protein core (des(16-18) or des(16-20)HP-RNase) induced the
spontaneous formation of stable dimers forming through the
domain swapping of the N-termini (Figure 5C), as confirmed by
the DVS cross-linking (304). Interestingly, the des(16-20) HP-
RNase mutant was recently discovered to form supramolecular
structures resembling amyloid-like rod-shaped fibrils (313). The
structural features of many dimerizing RNase 1 variants have
been deeply analyzed (314), while their antitumor activity has not
been investigated so far.
Onconase (ONC)
Extracted from the Rana pipiens oocytes, ONC is the unique
pancreatic-type RNase known to be remarkably cytotoxic in
its very stable native monomeric form (Figure 6A) together
with the less investigated, but also amphibian, amphinase
variant (27). Although being the smallest [104 AA, MW 11.8
kDa (28)] pancreatic-type RNase, and being also not highly
catalytically active, ONC displays the same catalytic triad (here
H10/K31/H97) and catalytic subsites similar to the RNase A ones
as well (316). Furthermore, beyond its antitumor effect, ONC
displays a prominent antiviral action by upregulating factors that
inhibit viral genome replication (317). ONC can penetrate cancer
cells because of its high basicity and favorable interaction with
the sialic acids moieties present on the malignant cell membranes
(318). Then, the crucial step is that ONC evades RI because
it lacks the key residues necessary to form a tight complex
with the inhibitor (152). ONC can attack tRNAs, as well as
other substrates, such as miRNAs, to exert its cytotoxic action
(319–321). Thus, at first glance, it would seem unnecessary to
produce ONC supramolecular structures to design anticancer
therapies (322); in fact, many positive results have been registered
with monomeric wt-ONC both in vitro and in vivo against
several still incurable tumors, like pleural mesothelioma, human
lung, glioma, pancreas and melanoma (27, 323–326). However,
the although reversible renal toxicity of ONC discovered upon
clinical trials (188) partially cooled down the initial enthusiasms.
This somehow alerts to find a way to enlarge the dimensions of
ONC moieties to make their filtration at the glomerular barrier
more difficult, and increasing its circulating half-life at the same
time. Consequently, many fusion immune-ONC derivatives have
been successfully built, as we reported in the previous paragraphs
and in Table 1 (218). Then, notwithstanding its remarkable
stability (TM ∼ 90
◦C), ONC has been recently discovered to
form a N-swapped dimer upon lyophilization from acetic acid
(Figure 6B) (200). Notably, this dimer displayed to be more
cytotoxic against pancreatic cancer cells than the corresponding
native ONC monomer (200). Unfortunately, ONC can swap
only its N-terminus, being the C-terminus locked by the
disulfide involving the Cys87 and Cys104 terminal residues. The
impossibility to swap more than one domain definitely reduces
the protein self-association propensity in general (243), and this
is certainly the case of ONC. Moreover, some ONC variants built
to unlock its C-terminus were found to be less stable than the
native enzyme (327, 328). This suggests a negative influence of
the free ONC C-terminus in the stabilization of the N-swapped
dimer, confirming also for ONC the reciprocal influence of the
N- and C-termini in the 3D-DS event involving RNases (200).
Consequently, the unique way known to date to obtain large
ONC homo-oligomers useful to escape renal filtration is the
use of the aforementioned trifunctional maleimide to produce
covalent derivatives (see Figure 1D) (172).
However, and finally, we mention a very recent study that
exploited both ONC and RNase A features to build a chimera able
to remarkably augment the tendency of the latter mammalian
enzyme to undergo 3D-DS oligomerization. This was obtained
by substituting in RNase A the 112–115 C-terminal loop,
comprising the Pro114 residue, with the shorter loop present in
ONC and devoid of this proline key-residue (271).
Microbial Barnase and Binase
Barnase and binase, both RNase variants of about 12 kDa,
belong to the RNase N1/T1 microbial superfamily. Importantly,
we firstly recall that in the past a mutant of fungal RNase
T1 was shown to acquire activity against ds-RNA upon
dimerization through 3D-DS (see Table 2) (329). Conversely,
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FIGURE 6 | Structures and models of non-mammalian RNases and of their oligomers. (A) Amphibian onconase (ONC); (B) N-swapped ONC dimer model (200); (C)
crystal structure of the N-swapped cyclic trimer of bacterial barnase (pdb 1YVS) (315); (D,E) two alternative models for the bacterial natively dimeric unswapped
binase, stabilized by electrostatic interactions at the subunits’ interface (90).
the wt-RNase T1 is not cytotoxic, being unable to enter the
cells if it is not pre-incorporated into a HVJ cell-penetrating
envelope vector (330). Then, barnase was in turn discovered
to form a cyclic domain-swapped “flower-like” trimeric adduct
(Figure 6C) (315). Furthermore, barnase interaction with its
inhibitor barstar has been recently discovered to induce the
lysis of staphylococcal bacteria (112). We underline again
that barnase was derivatized, either as a monomer or as a
dimer, also with immuno-peptides to form Immuno-RNase
derivatives that were cytotoxic against breast and ovarian
cancers (87–89). Binase, instead, is a variant known to display
a remarkable toxicity toward many tumor cells (83, 91),
and is also accompanied with a relevant antiviral activity
(92, 93, 331). Binase has been subsequently found to exist
as a natural dimer (90, 332), and the presence of the
swapping of the N-terminal domain has been strongly suggested.
However, two alternative structural models did not confirm
the actual presence of 3D-DS: in fact, two structures showing
electrostatic interactions have been proposed as being able to
stabilize the interface between the two monomeric subunits
of the native binase dimer (Figures 6D,E) (90). Interestingly,
the variant balifase has also been characterized, apparently
displaying a lower cytotoxicity than binase (84). Hence,
further investigations on the structural determinants governing
the important antitumor activity of these microbial RNases
certainly deserve be performed to design future efficacious anti-




Several aspects of the catalytic, immunomodulatory and
antitumor properties displayed by many RNases and by their
oligomeric derivatives have been described in this review. Some
results useful for therapy against still incurable cancers have
been underlined or suggested as well. Although promising
results have been already obtained with some RNases, and
especially with ONC, improvements are necessary in terms
of potentiating cytotoxicity and contemporarily attenuating or
deleting undesired side-effects. To this end, RNases homo- or
hetero-dimerization, or more extensive oligomerization, might
certainly represent an efficacious strategy to be sharply tuned.
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The hetero-crosslinked immuno-RNases or the homo or
hetero fusion-proteins have certainly offered promising results
that could be hopefully transferred toward clinical use in the
next future. However, the spontaneous or artificially induced
non-covalent RNase self-association may also represent a fruitful
pathway to produce active RNase derivatives.
Hence, the oligomerization tendency of, and the products
formed by RNase A, BS-RNase, RNase 1 and ONC may suggest
a smart future approach to build complex chimera products.
From what has been reported, it emerges that the determinants
driving a RNase to dimerize or oligomerize in a way that can
make it cytotoxic depend on several features, comprising 3D-DS
propensity, stability, basic nature of key-residues and geometry
of the supramolecular adduct(s) formed. These features can affect
crucial steps correlated with cytotoxicity, such as the interaction
with the cell membrane, ability to enter the cytosol or to evade RI.
Therefore, and finally, the RNase oligomerization strategy
should drive toward products accompanied with relevant
antitumor activity but devoid of undesired side-effects.Moreover,
the RNase derivatives should be characterized by a satisfactory
half-life in the circulatory system, to reach more easily the tumor
place, thus allowing successful applications in therapy.
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